secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021213
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics Q1 net product sales up 26% to $29.6M; net loss narrows to $32.8M
--------------------------------------------------------------------------------

- Net product sales $29.6M vs $23.5M in Q1 2022, driven by oncology franchise growth of 15%.
- Net loss $32.8M ($0.27/share), improved from $63.9M ($0.63/share) a year ago.
- Cash and investments $60.0M at March 31, 2023, down from $84.9M at Dec. 31, 2022.
- Appointed Craig Collard as CEO in April; APONVIE launched in March with $0.3M initial sales.
- ZYNRELEF sNDA PDUFA date set for Oct. 23, 2023; 907 unique accounts have purchased since launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017023021213/0000950170-23-021213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017023021213/hrtx-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer